Rhelion Life Sciences Corp. TRUFF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 134.40K | 638.10K | 907.20K | 547.50K | 399.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 134.40K | 638.10K | 907.20K | 547.50K | 399.70K |
| Cost of Revenue | 11.80K | 303.80K | 650.50K | 309.90K | 290.90K |
| Gross Profit | 122.60K | 334.30K | 256.70K | 237.60K | 108.80K |
| SG&A Expenses | 1.10M | 1.13M | 1.11M | 958.90K | 1.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.18M | 1.43M | 1.77M | 1.27M | 1.31M |
| Operating Income | -1.04M | -795.50K | -858.90K | -723.30K | -911.80K |
| Income Before Tax | -1.08M | -2.50M | -1.03M | -894.10K | -856.30K |
| Income Tax Expenses | -- | -170.90K | -20.50K | -30.20K | -15.20K |
| Earnings from Continuing Operations | -1.08M | -2.33M | -1.01M | -863.90K | -841.10K |
| Earnings from Discontinued Operations | -280.60K | -- | -- | -- | 85.30K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 16.00K | 488.50K | 23.20K | 16.80K | 12.50K |
| Net Income | -1.35M | -1.84M | -989.10K | -847.10K | -743.30K |
| EBIT | -1.04M | -795.50K | -858.90K | -723.30K | -911.80K |
| EBITDA | -995.10K | -748.60K | -808.80K | -668.40K | -862.20K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 551.45M | 424.64M | 417.59M | 412.25M | 411.87M |
| Average Diluted Shares Outstanding | 551.45M | 424.64M | 417.59M | 412.25M | 411.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |